Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians

Gene

Volumn 518, Issue 2, 2013, Pages 479-482

  Zheng, Ming Hua ^a,b   Li, Yu ^b   Xiao, Dong Dong ^a,b   Shi, Ke Qing ^a,b   Fan, Yu Chen ^c   Chen, Li Li ^a,b   Liu, Wen Yue ^a,b   Luo, Ying Wan ^a,b   Chen, Yong Ping ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Hepatitis C virus; Interleukin 28B; Single nucleotide polymorphisms; Spontaneous clearance; Systematic review

Indexed keywords

INTERLEUKIN 28B;

ARTICLE; CAUCASIAN; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; VIRAL CLEARANCE;

EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REMISSION, SPONTANEOUS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84875381700     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.067     Document Type: Article

References (31)

1. Brand S., et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G960-G968.
2. Conjeevaram H.S., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
3. di Iulio J., et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011, 53:1446-1454.
4. Di Martino V., et al. Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology 2011, (p.). 10.1002/hep.24480.
5. Dring M.M., et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5736-5741.
6. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
7. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
8. Grebely J., et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216-1224.
9. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
10. Hong S.H., Cho O., Kim K., Shin H.J., Kotenko S.V., Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007, 126:245-249.
11. Hou W., et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J. Virol. 2009, 83:3834-3842.
12. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999, 340:1228-1233.
13. Knapp S., et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 2011, 141:320-325.
14. Kotenko S.V., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
15. Marcello T., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131:1887-1898.
16. Melchjorsen J., Siren J., Julkunen I., Paludan S.R., Matikainen S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J. Gen. Virol. 2006, 87:1099-1108.
17. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 2006, 13:34-41.
18. Montes-Cano M.A., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
19. Munir S., et al. Hepatitis C treatment: current and future perspectives. Virol. J. 2010, 7:296.
20. Page K., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J. Infect. Dis. 2009, 200:1216-1226.
21. Rauch A., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. (1345 e1-7).
22. Seeff L.B. The natural history of chronic hepatitis C virus infection. Clin. Liver Dis. 1997, 1:587-602.
23. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
24. Shi K.Q., Liu W.Y., Lin X.F., Fan Y.C., Chen Y.P., Zheng M.H. Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-alpha plus ribavirin: a meta-analysis. Gene 2012, 507:27-35.
25. Stuck A.E., Rubenstein L.Z., Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ 1998, 316:469. (author reply 470-1).
26. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
27. Thomas D.L., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
28. Thomas D.L., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
29. Tillmann H.L., et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139:1586-1592. (1592 e1).
30. Wang C.C., et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J. Infect. Dis. 2007, 196:1474-1482.
31. Zhang L., et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J. Hepatol. 2011, 55:289-298.